Teva Pharmaceutical Industries LimitedTEVANYSE
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
93.85%
↑ 112% above average
Average (39q)
-761.58%
Historical baseline
Range
High:1889.66%
Low:-19875.00%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 93.85% |
| Q2 2025 | -12.33% |
| Q1 2025 | 1889.66% |
| Q4 2024 | 43.14% |
| Q3 2024 | -920.00% |
| Q2 2024 | 97.71% |
| Q1 2024 | -128.84% |
| Q4 2023 | 119.77% |
| Q3 2023 | 152.60% |
| Q2 2023 | -4930.77% |
| Q1 2023 | 98.48% |
| Q4 2022 | -304.06% |
| Q3 2022 | 144.15% |
| Q2 2022 | -33.10% |
| Q1 2022 | -1014.10% |
| Q4 2021 | -87.48% |
| Q3 2021 | 7.04% |
| Q2 2021 | 34.10% |
| Q1 2021 | 6.90% |
| Q4 2020 | 109.35% |
| Q3 2020 | -2609.83% |
| Q2 2020 | -9.42% |
| Q1 2020 | 29.05% |
| Q4 2019 | 282.72% |
| Q3 2019 | 87.42% |
| Q2 2019 | -580.60% |
| Q1 2019 | 104.24% |
| Q4 2018 | -19875.00% |
| Q3 2018 | 214.29% |
| Q2 2018 | -100.92% |
| Q1 2018 | 111.72% |
| Q4 2017 | -3543.65% |
| Q3 2017 | 106.59% |
| Q2 2017 | -741.34% |
| Q1 2017 | 753.28% |
| Q4 2016 | -117.91% |
| Q3 2016 | 111.91% |
| Q2 2016 | -69.01% |
| Q1 2016 | 25.13% |
| Q4 2015 | -7.82% |